Combined use of dendritic cells enhances specific antileukemia immunity by leukemia cell-derived heat shock protein 70 in a mouse model with minimal residual leukemia cells

International Journal of Hematology

Volumn 84, Issue 5, 2006, Pages 449-458

  Iuchi, Yasuyuki ^a   Torimoto, Yoshihiro ^a   Sato, Kazuya ^a   Tamura, Yasuaki ^b   Jimbo, Junko ^a   Inamura, Junki ^a   Shindo, Motohiro ^a   Ikuta, Katsuya ^a   Ohnishi, Kouhei ^a   Kohgo, Yutaka ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

Bone marrow transplantation; Dendritic cells; Heat shock protein; Immunotherapy; Leukemia

Indexed keywords

ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; HEAT SHOCK PROTEIN 70; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LEUKEMIA; BONE MARROW TRANSPLANTATION; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL STRAIN A20; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; FEMALE; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGICAL TOLERANCE; LEUKEMIA; LEUKEMIA CELL; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; SPLEEN CELL; STEM CELL TRANSPLANTATION; TUMOR IMMUNITY;

ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HSP70 HEAT-SHOCK PROTEINS; IMMUNITY, CELLULAR; LEUKEMIA, B-CELL; MICE; MICE, INBRED BALB C; NEOPLASM PROTEINS; NEOPLASM, RESIDUAL; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, ISOGENEIC; VACCINATION;

EID: 33846111467     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.06003     Document Type: Article

References (51)

1. Przepiorka D, Srivastava PK. Heat shock protein-peptide complexes as immunotherapy for human cancer. Mol Med Today. 1998;4:478-484.
2. Nieland TJF, Tan MCA, Monne-van Muijien M, Koning F, Kruisbeek AM, van Bleek GM. Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein GP96/GRP94. Proc Natl Acacl Sci U S A. 1996;93:6135-6139.
3. Pockley AG. Heat shock proteins as regulators of the immune response. Lancet. 2003;362:469-476.
4. Srivastava PK, Udono H, Blachere N, Li Z. Heat shock proteins transfer peptide during antigen processing and CTL priming. Immunogenetics. 1994;39:93-98.
5. Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity. 1998;8:657-665.
6. Srivastava PK. Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol. 2002;2:185-194.
7. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science. 1997;278:117-120.
8. Linker CA. Autologous stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplant. 2003;31:731-738.
9. Antman KH, Rowlings PA, Vaughan WP, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol. 1997;15:1870-1879.
10. Brunvand MW, Bensinger WI, Sokl E, et al. High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow transplantation and peripheral blood stem cells. Bone Marrow Transplant. 1996;18:131-141.
11. Margolin KA, Negrin RS, Wong KK, Chatterjee S, Wright C, Forman SJ. Cellular immunotherapy and autologous transplantation for hematologic malignancy. Immunol Rev. 1997;157:231-240.
12. Rosenberg SA. Progress in human tumor immunology and immunotherapy. Nature. 2001;411:380-384.
13. Gilboa E. The makings of a tumor rejection antigen. Immunity. 1999;11:263-270.
14. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol. 2000;18:245-273.
15. Sato K, Torimoto Y, Tamura Y, et al. Immunotherapy using heat-shock protein preparations of leukemia cells after syngeneic bone marrow transplantation in mice. Blood. 2001;98:1852-1857.
16. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
17. Heiser A, Coleman D, Dannull J, et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest. 2002;109:409~417.
18. Buchler T, Michalek J, Kovarova L, Musilova R, Hajek R. Dendritic cell-based immunotherapy for the treatment of hematological malignancies. Hematology. 2003;8:97-104.
19. Romero P, Dunbar PR, Valmori D, et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med. 1998;188:1641-1650.
20. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity. 2001;14:303-313.
21. Chen W, Syldath U, Bellmann K, Burkart V, Kolb H. Human 60-kDa heat-shock protein: a danger signal to the innate immune system. J Immunol. 1999;162:3212-3219.
22. Cho BK, Palliser D, Guillen E, et al. A proposed mechanism for the induction of cytotoxic T lymphocyte production by heat shock fusion proteins. Immunity. 2000;12:263-272.
23. Breloer M, Fleischer B, von Bonin A. In vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins. J Immunol. 1999;162:3141-3147.
24. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a maturation signal to dendritic cells and activate the NF-κB pathway. Int Immunol. 2000;12:1539-1546.
25. Kim KJ, Langevin CK, Merwin RM, Sachs DH, Asfsky R. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J Immunol. 1979;122:549-554.
26. Chesebro B, Wehrly K, Chesebro K, Portis J. Characterization of 1a8 antigen, Thy-1.2 antigen, complement receptors, and virus production in a group of murine virus-induced leukemia cell lines. J Immunol. 1976;117:1267-1274.
27. Corbett TH, Griswold DP Jr, Robert BJ, Peckhan JC, Schabel FM Jr. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assay, with a note on carcinogen structure. Cancer Res. 1975;35:2434-2439.
28. Cikes M, Friberg S Jr, Klein G. Progressive loss of H-2 antigens with concomitant increase of cell-surface antigen(s) determined by Moloney leukemia virus in cultured murine lymphomas. J Natl Cancer Inst. 1973;50:347-362.
29. Srivastava PK. Purification of heat shock protein-peptide complexes for use in vaccination against cancers and intracellular pathogens. Methods. 1997;12:165-171.
30. Obayashi T, Tamura H, Tanaka S, et al. A new chromogenic endotoxin-specific assay using recombined Limulus coagulation enzymes and its clinical applications. Clin Chim Acta. 1985;149:55-65.
31. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med. 1992;176:1693-1702.
32. Uharek L, Glass B, Gaska T, Gassmann W, Loeffler H, Mueller-Ruchholts W. Influence of donor lymphocytes on the incidence of primary graft failure after allogeneic bone marrow transplantation in a murine model. Br J Haematol. 1994;88:79-87.
33. Glass B, Uharek L, Zeis M, et al. Allogeneic peripheral blood progenitor cell transplantation in a murine model: evidence for an improved graft-versus-leukemia effect. Blood. 1997;90:1694-1700.
34. Frei III E, Freireich EJ. Progress and perspectives in the chemotherapy of acute leukemia. Adv Chemother. 1965;2:269-298.
35. Tschopp J, Nabholz M. Perforin mediated target cell lysis by cytolytic T lymphocytes. Annu Rev Immunol. 1990;8:279-302.
36. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med. 1999;50:507-529.
37. Ingram SB, O'Rourke MG. DC therapy for metastatic melanoma. Cytotherapy. 2004;6:148-153.
38. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328-332.
39. Feng H, Zeng Y, Whitesell L, Katsanis E. Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity. Blood. 2001;97:3505-3512.
40. Glass B, Uharek L, Zeis M, Loeffler H, Mueller-Ruchholtz W, Gassmann W. Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells. Br J Haematol. 1996;93:412-420.
41. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000;18:3894-3903.
42. + progenitor-derived dendritic cell vaccine. Cancer Res. 2001;61:6451-6158.
43. Mortarini R, Anichini A, Di Nicola M, et al. Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)- specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. Cancer Res. 1997;57:5534-5541.
44. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med. 2001;193:233-238.
45. Steinman RM, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med. 2000;191:411-416.
46. Kuppner MC, Gastpar R, Gelwer S, et al. The role of heat shock protein (hsp70) in dendritic cell maturation: hsp70 induces the maturation of immature dendritic cells but reduces DC differentiation from monocyte precursors. Eur J Immunol. 2001;31:1602-1609.
47. Qiu J, Li GW, Sui YF, Song HP, Si SY, Ge W. Heat-shocked tumor cell lysate-pulsed dendritic cells induce effective anti-tumor immune response in vivo. World J Gastroenterol. 2006;12:473-478.
48. Qian J, Wang S, Yang J, et al. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96. Clin Cancer Res. 2005;11:8808-8815.
49. Dai S, Wan T, Wang B, et al. More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells. Clin Cancer Res. 2005;11:7554-7755.
50. Oki Y, Younes A. Heat shock protein-based cancer vaccines. Expert Rev Vaccines. 2004;3:403-411.
51. Roskrow MA, Dilloo D, Suzuki N, Zhong W, Rooney CM, Brenner MK. Autoimmune disease induced by dendritic cell immunization against leukemia. Leak Res. 1999;23:549-555.